AAPL315.62-0.60 (-0.19%) ▼|ABBV250.37+1.59 (+0.64%) ▲|ABT105.40-0.12 (-0.11%) ▼|ACN177.31-1.72 (-0.96%) ▼|ADBE255.49-1.78 (-0.69%) ▼|AMAT467.78-5.01 (-1.06%) ▼|AMD519.22+13.48 (+2.67%) ▲|AMGN392.11-1.07 (-0.27%) ▼|AMT175.37-0.37 (-0.21%) ▼|AMZN252.15-4.83 (-1.88%) ▼|AVGO363.76-4.81 (-1.30%) ▼|AXP322.54-3.57 (-1.09%) ▼|BA208.00-2.73 (-1.30%) ▼|BAC62.90+0.51 (+0.81%) ▲|BKNG173.08-7.23 (-4.01%) ▼|BLK1,075.34-20.04 (-1.83%) ▼|BMY64.31-0.39 (-0.60%) ▼|BNY163.26+0.41 (+0.25%) ▲|BRK-B507.31+1.48 (+0.29%) ▲|C138.43+1.69 (+1.23%) ▲|CAT818.05-4.43 (-0.54%) ▼|CL88.02-0.39 (-0.44%) ▼|CMCSA24.56-1.77 (-6.72%) ▼|COF212.55-1.42 (-0.66%) ▼|COP137.24+2.20 (+1.63%) ▲|COST901.49-8.69 (-0.95%) ▼|CRM244.28-4.85 (-1.94%) ▼|CSCO109.28+0.11 (+0.10%) ▲|CVS95.82-0.25 (-0.26%) ▼|CVX214.01+4.21 (+2.01%) ▲|DE677.21-3.53 (-0.52%) ▼|DHR205.08-0.15 (-0.07%) ▼|DIS104.43-0.63 (-0.60%) ▼|DUK120.32-0.92 (-0.76%) ▼|EMR151.08-1.07 (-0.70%) ▼|FDX310.14-3.99 (-1.27%) ▼|GD352.72-3.87 (-1.08%) ▼|GE326.49-8.42 (-2.52%) ▼|GEV953.40-17.91 (-1.84%) ▼|GILD145.74-0.90 (-0.61%) ▼|GM84.75-1.04 (-1.21%) ▼|GOOG328.54-6.85 (-2.04%) ▼|GOOGL330.99-7.38 (-2.18%) ▼|GS1,031.66-4.87 (-0.47%) ▼|HD311.17-2.53 (-0.81%) ▼|HON205.26-2.98 (-1.43%) ▼|IBM239.46+7.37 (+3.18%) ▲|INTC106.23+1.76 (+1.68%) ▲|INTU314.34-4.59 (-1.44%) ▼|ISRG352.63+2.47 (+0.71%) ▲|JNJ267.95-1.17 (-0.43%) ▼|JPM355.39+1.88 (+0.53%) ▲|KO87.79-0.58 (-0.65%) ▼|LIN466.02-2.36 (-0.50%) ▼|LLY1,125.26+1.35 (+0.12%) ▲|LMT526.31-9.84 (-1.84%) ▼|LOW198.71-2.09 (-1.04%) ▼|LRCX314.93-5.50 (-1.71%) ▼|MA569.83-1.06 (-0.19%) ▼|MCD254.55-1.26 (-0.49%) ▼|MDLZ62.28+0.65 (+1.05%) ▲|MDT92.07-0.32 (-0.35%) ▼|META655.08+41.60 (+6.78%) ▲|MMM164.39-3.13 (-1.87%) ▼|MO67.83-0.34 (-0.50%) ▼|MRK147.81-0.65 (-0.44%) ▼|MS215.92-0.32 (-0.15%) ▼|MSFT491.59-2.37 (-0.48%) ▼|MU1,029.05+28.79 (+2.88%) ▲|NEE83.08-0.76 (-0.90%) ▼|NFLX76.13-0.64 (-0.83%) ▼|NKE37.26-0.85 (-2.22%) ▼|NOW131.85-2.36 (-1.76%) ▼|NVDA223.79-1.94 (-0.86%) ▼|ORCL162.64+0.12 (+0.07%) ▲|PEP137.14-1.31 (-0.94%) ▼|PFE27.81+0.02 (+0.07%) ▲|PG142.74-2.84 (-1.95%) ▼|PLTR170.33+0.03 (+0.01%) ▲|PM185.58+0.85 (+0.46%) ▲|QCOM175.42+1.33 (+0.76%) ▲|RTX198.76-0.05 (-0.03%) ▼|SBUX100.83-1.19 (-1.16%) ▼|SCHW107.34+0.47 (+0.44%) ▲|SO88.21-0.78 (-0.88%) ▼|SPG206.38-3.25 (-1.55%) ▼|T25.10-0.51 (-1.97%) ▼|TMO608.81+5.79 (+0.96%) ▲|TMUS177.96-3.73 (-2.05%) ▼|TSLA369.13+0.97 (+0.26%) ▲|TXN261.45+2.53 (+0.98%) ▲|UBER71.71-1.42 (-1.94%) ▼|UNH392.19-8.65 (-2.16%) ▼|UNP284.77-3.68 (-1.28%) ▼|UPS99.34-1.15 (-1.14%) ▼|USB62.18-0.31 (-0.50%) ▼|V368.41-0.23 (-0.06%) ▼|VZ49.60-0.82 (-1.62%) ▼|WFC89.63+1.67 (+1.90%) ▲|WMT105.88-0.17 (-0.16%) ▼|XOM164.66+4.00 (+2.49%) ▲|AAPL315.62-0.60 (-0.19%) ▼|ABBV250.37+1.59 (+0.64%) ▲|ABT105.40-0.12 (-0.11%) ▼|ACN177.31-1.72 (-0.96%) ▼|ADBE255.49-1.78 (-0.69%) ▼|AMAT467.78-5.01 (-1.06%) ▼|AMD519.22+13.48 (+2.67%) ▲|AMGN392.11-1.07 (-0.27%) ▼|AMT175.37-0.37 (-0.21%) ▼|AMZN252.15-4.83 (-1.88%) ▼|AVGO363.76-4.81 (-1.30%) ▼|AXP322.54-3.57 (-1.09%) ▼|BA208.00-2.73 (-1.30%) ▼|BAC62.90+0.51 (+0.81%) ▲|BKNG173.08-7.23 (-4.01%) ▼|BLK1,075.34-20.04 (-1.83%) ▼|BMY64.31-0.39 (-0.60%) ▼|BNY163.26+0.41 (+0.25%) ▲|BRK-B507.31+1.48 (+0.29%) ▲|C138.43+1.69 (+1.23%) ▲|CAT818.05-4.43 (-0.54%) ▼|CL88.02-0.39 (-0.44%) ▼|CMCSA24.56-1.77 (-6.72%) ▼|COF212.55-1.42 (-0.66%) ▼|COP137.24+2.20 (+1.63%) ▲|COST901.49-8.69 (-0.95%) ▼|CRM244.28-4.85 (-1.94%) ▼|CSCO109.28+0.11 (+0.10%) ▲|CVS95.82-0.25 (-0.26%) ▼|CVX214.01+4.21 (+2.01%) ▲|DE677.21-3.53 (-0.52%) ▼|DHR205.08-0.15 (-0.07%) ▼|DIS104.43-0.63 (-0.60%) ▼|DUK120.32-0.92 (-0.76%) ▼|EMR151.08-1.07 (-0.70%) ▼|FDX310.14-3.99 (-1.27%) ▼|GD352.72-3.87 (-1.08%) ▼|GE326.49-8.42 (-2.52%) ▼|GEV953.40-17.91 (-1.84%) ▼|GILD145.74-0.90 (-0.61%) ▼|GM84.75-1.04 (-1.21%) ▼|GOOG328.54-6.85 (-2.04%) ▼|GOOGL330.99-7.38 (-2.18%) ▼|GS1,031.66-4.87 (-0.47%) ▼|HD311.17-2.53 (-0.81%) ▼|HON205.26-2.98 (-1.43%) ▼|IBM239.46+7.37 (+3.18%) ▲|INTC106.23+1.76 (+1.68%) ▲|INTU314.34-4.59 (-1.44%) ▼|ISRG352.63+2.47 (+0.71%) ▲|JNJ267.95-1.17 (-0.43%) ▼|JPM355.39+1.88 (+0.53%) ▲|KO87.79-0.58 (-0.65%) ▼|LIN466.02-2.36 (-0.50%) ▼|LLY1,125.26+1.35 (+0.12%) ▲|LMT526.31-9.84 (-1.84%) ▼|LOW198.71-2.09 (-1.04%) ▼|LRCX314.93-5.50 (-1.71%) ▼|MA569.83-1.06 (-0.19%) ▼|MCD254.55-1.26 (-0.49%) ▼|MDLZ62.28+0.65 (+1.05%) ▲|MDT92.07-0.32 (-0.35%) ▼|META655.08+41.60 (+6.78%) ▲|MMM164.39-3.13 (-1.87%) ▼|MO67.83-0.34 (-0.50%) ▼|MRK147.81-0.65 (-0.44%) ▼|MS215.92-0.32 (-0.15%) ▼|MSFT491.59-2.37 (-0.48%) ▼|MU1,029.05+28.79 (+2.88%) ▲|NEE83.08-0.76 (-0.90%) ▼|NFLX76.13-0.64 (-0.83%) ▼|NKE37.26-0.85 (-2.22%) ▼|NOW131.85-2.36 (-1.76%) ▼|NVDA223.79-1.94 (-0.86%) ▼|ORCL162.64+0.12 (+0.07%) ▲|PEP137.14-1.31 (-0.94%) ▼|PFE27.81+0.02 (+0.07%) ▲|PG142.74-2.84 (-1.95%) ▼|PLTR170.33+0.03 (+0.01%) ▲|PM185.58+0.85 (+0.46%) ▲|QCOM175.42+1.33 (+0.76%) ▲|RTX198.76-0.05 (-0.03%) ▼|SBUX100.83-1.19 (-1.16%) ▼|SCHW107.34+0.47 (+0.44%) ▲|SO88.21-0.78 (-0.88%) ▼|SPG206.38-3.25 (-1.55%) ▼|T25.10-0.51 (-1.97%) ▼|TMO608.81+5.79 (+0.96%) ▲|TMUS177.96-3.73 (-2.05%) ▼|TSLA369.13+0.97 (+0.26%) ▲|TXN261.45+2.53 (+0.98%) ▲|UBER71.71-1.42 (-1.94%) ▼|UNH392.19-8.65 (-2.16%) ▼|UNP284.77-3.68 (-1.28%) ▼|UPS99.34-1.15 (-1.14%) ▼|USB62.18-0.31 (-0.50%) ▼|V368.41-0.23 (-0.06%) ▼|VZ49.60-0.82 (-1.62%) ▼|WFC89.63+1.67 (+1.90%) ▲|WMT105.88-0.17 (-0.16%) ▼|XOM164.66+4.00 (+2.49%) ▲|

28.6 C

New York

Wednesday, September 9, 2026

/C O R R E C T I O N — Partillion Bioscience/

Holdun Family Office (Bahamas) Limited Confirms the Conclusion of its Licensed Wealth Management Business

Drivvr AI Welcomes Automotive Marketing Veteran Brian Voss as National Sales Director

Tag: blood

Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management

Fangzhou Inc., a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company.

New APOE4 App Uses AI Digital Twins to Help 25% of Population at High Alzheimer’s Risk

Phoenix platform matches users with genetically similar people to predict which interventions actually work.

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy (neffy^® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

Roundhouse Provisions Basecamp Complete Wins “Meal Replacement Product of the Year” at 2025 Mindful Awards

Plant-Based, Chuck Norris-Approved Nutrition Shake Recognized for Exceptional Convenience, Taste, and Nutritional Balance HOUSTON, July 18, 2025 /PRNewswire/ -- Roundhouse Provisions®, the trusted wellness brand...

Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University...

TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1 billion (USD 7.3...

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

PhenQ – Round the Clock Weightloss: 2025’s Strongest 24/7 Fat-Burning System for Appetite Control, Sleep-Supported Metabolism & Craving Relief

2025’s Strongest 24/7 Fat-Burning System for Appetite Control, Sleep-Supported Metabolism & Craving Relief

2025’s Strongest 24/7 Fat-Burning System for Appetite Control, Sleep-Supported Metabolism & Craving Relief

Female Muscle Growth: How CrazyBulk’s Natural Legal Steroids Are Reshaping Muscle Building Supplements For Bodybuilding Women

Discover how CrazyBulk’s natural legal steroids are transforming muscle building supplements for bodybuilding women seeking safe, effective female muscle growth.

Discover how CrazyBulk’s natural legal steroids are transforming muscle building supplements for bodybuilding women seeking safe, effective female muscle growth.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsBlood

/C O R R E C T I O N — Partillion Bioscience/

Holdun Family Office (Bahamas) Limited Confirms the Conclusion of its Licensed Wealth Management Business

Drivvr AI Welcomes Automotive Marketing Veteran Brian Voss as National Sales Director

Tag: blood

Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management

New APOE4 App Uses AI Digital Twins to Help 25% of Population at High Alzheimer’s Risk

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Roundhouse Provisions Basecamp Complete Wins “Meal Replacement Product of the Year” at 2025 Mindful Awards

Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University...

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

PhenQ – Round the Clock Weightloss: 2025’s Strongest 24/7 Fat-Burning System for Appetite Control, Sleep-Supported Metabolism & Craving Relief

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine

Female Muscle Growth: How CrazyBulk’s Natural Legal Steroids Are Reshaping Muscle Building Supplements For Bodybuilding Women

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us